Mounjaro®
Starting from £179.99/mo
Start journey Learn moreJenni Murray has spoken publicly about using Mounjaro for weight loss, and the media coverage that followed brought the medicine's side effects into sharp focus. Mounjaro (tirzepatide) is a prescription-only treatment, and like every effective medicine it carries a real side-effect profile — one that deserves honest, unspun examination rather than headlines. The decision about whether tirzepatide is right for you belongs with a qualified prescriber, not a newspaper column. This page sets out what the clinical evidence actually shows, what to watch for, and when to seek help — so you can have an informed conversation rather than a worried one.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
When a well-known public figure talks about a medicine's effects, it shapes the questions people bring to their prescribers, sometimes helpfully, sometimes with anxiety attached that the data doesn't fully support. Jenni Murray's candid account of her experience with Mounjaro put side effects on the front page. That's not a bad thing. Tirzepatide is a prescription-only medicine and its side-effect profile is real, documented and worth understanding properly before you start.
The core decision for most readers landing here isn't whether side effects exist (they do) it's whether the profile is manageable given your own health picture. That's a clinical judgement, not a media one. What you can do right now is understand what the evidence shows, so the conversation with a prescriber is a productive one.
A good starting point is the Mounjaro overview page, which covers the medicine's mechanism and licensed uses, before you read through the side-effect detail below.
The NHS's patient information on tirzepatide confirms that the most frequently reported effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, indigestion and burping. Fatigue, headache, dizziness and reactions at the injection site are also reported. NHS guidance on tirzepatide notes these are typically most pronounced after you first start the medicine or following a dose step-up, and for many people they ease within one to two weeks as the body adjusts.
The titration schedule (starting at the 2.5mg dose purely to let your system settle before therapeutic doses are introduced) exists precisely because this pattern was observed in clinical trials. Thousands of adults took part in the SURMOUNT-1 trial alone, and the GI side-effect picture seen there is consistent with what prescribers observe in practice. If you've read that someone had a particularly rough first fortnight, that broadly fits what the data would predict; if you've read that Mounjaro is uniformly intolerable, that doesn't.
For a closer look at individual effects by dose, the five most commonly reported Mounjaro side effects are covered in more detail separately.
Not every side effect resolves on its own, and some warrant prompt assessment. In January 2026 the MHRA issued a Drug Safety Update drawing clinicians' and patients' attention to acute pancreatitis as a known risk with GLP-1 receptor agonist medicines. It is infrequent, but it can be serious. The symptom to know is severe abdominal pain (persistent, significant, possibly reaching through to the back) with or without vomiting. That combination should prompt a call to 111 or a visit to A&E, not a message to your online pharmacy at 9pm.
Other symptoms that justify prompt contact with a healthcare professional include signs of gallbladder problems (upper right abdominal pain, especially after eating), symptoms of significant dehydration from prolonged vomiting or diarrhoea, any allergic reaction (facial swelling, difficulty breathing, widespread rash), and low mood or thoughts of self-harm, which should always be taken seriously regardless of cause.
You can report a suspected side effect (whether or not you're certain it's linked to the medicine) via the MHRA's Yellow Card scheme. Reporting helps regulators build a clearer picture over time, particularly for newer medicines still under additional monitoring.
If you're already taking Mounjaro and want to understand what to expect in the very first days, the day-one side effects page addresses that specific period.
Some people start Mounjaro and notice very little in the way of side effects. That's not unusual, and it isn't evidence the medicine isn't working. The Mounjaro and no side effects page addresses this directly for anyone who's concerned by the absence of a reaction they were expecting.
At the other end, some people find the GI effects particularly difficult, enough to prompt a pause or a conversation about whether to continue. That's a legitimate clinical discussion, not a failure. The what to do if Mounjaro gives you side effects page covers practical strategies, and any significant concern should go back to the prescriber who approved your treatment.
At nume, side effects are part of the consultation from the outset, a prescriber reads your full health picture before approving treatment, and our aftercare team is available seven days a week for questions that come up afterwards. There's no algorithm triaging your messages. If you'd like to understand whether tirzepatide is clinically suitable for you, the right next step is the free consultation. Our prescribers discuss suitability and side effects as part of that process, not as an afterthought. You can also read about the full Mounjaro side effects profile, or check your eligibility to start the conversation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.